Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04874012 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Taurine Effect on Glycemic, Lipidic and Inflammatory Profile in Individuals With Type 2 Diabetes

Study acronym: TAUGLIP-DM2
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of Oct 2025 to Dec 20, 2025 Show 4 more changesShow less
    • Study completion pushed from Dec 2025 to Dec 1, 2026
    • Eligibility criteria expanded, about 11 words
    • Site contact updated
    • Publications: details revised at 8 of 8 entries
  2. Primary completion date: Dec 30, 2024 to Oct 2025
    • Study completion date: Mar 1, 2025 to Dec 2025
    v6
  3. Primary completion date: Aug 1, 2024 to Dec 30, 2024
    • Study completion date: Dec 1, 2024 to Mar 1, 2025
    v5
  4. Primary completion date: Aug 1, 2023 to Aug 1, 2024
    • Study completion date: Dec 1, 2023 to Dec 1, 2024
    • Site details revised
    • Study title shortened, about 1 word
    v4
  5. Primary completion date: Apr 1, 2023 to Aug 1, 2023
    • Study completion date: Apr 1, 2023 to Dec 1, 2023
    • Site contact updated
    v3
  6. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of May 1, 2021 to Jun 12, 2021
    • Site details revised
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Type 2 diabetes mellitus (DM2) is characterized by chronic hyperglycemia, which is a risk factor for comorbidities and death. Although conventional pharmacotherapy is effective, some individuals do not reach the glycemic targets, requiring adjuvant therapies. Taurine is a semi-essential amino acid with antioxidant and osmoregulatory properties, commonly used as a nutritional supplement. Pre-clinical studies show its effectiveness in reducing blood glucose and cholesterol, but there are no well-conducted clinical studies evaluating the effect of taurine on glycated hemoglobin. Additionally, animal models showed that taurine had a protective effect from diabetic nephropathy. The hypothesize of this study is that taurine administration improves the glycemic, lipid, inflammatory, and anthropometric parameters in DM2 individuals.
Trial Details
NCT Number NCT04874012
Lead Sponsor Hospital de Clinicas de Porto Alegre
Conditions
(from sponsor)		 Diabetes Mellitus, Type 2
Related terms Diabetes Mellitus, Type 2, Glucose Metabolism Disorders, Inflammation
Enrollment 94 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov